In Abida et al.’s study [17], 11 MSI-H/dMMR castration-resistant prostate cancer patients underwent anti-PD-1/PD-L1 treatment, with six (54.5%) experiencing more than a 50% reduction in prostate-specific antigen levels and four exhibiting radiographic responses. The gene discussed is PDCD1; the disease is prostate cancer.